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We read with interest the recent article by Kesten and colleagues (2017) which explored the 
acceptability of low dead space syringes (LDSS) among people who inject drugs (PWID) and Needle 
and Syringe Exchange programme staff, and the implications of their introduction. This research 
concluded that detachable LDSS are likely to be acceptable and that their introduction should be 
accompanied by an intervention which incorporates training, education, persuasion and restriction 
components.  
Glasgow is currently in the midst of an outbreak of HIV infection amongst PWID. In 2015, 47 new HIV 
diagnoses among PWID were recorded in Glasgow compared to an annual average of around 10 in 
this population (Public Health England, Health Protection Scotland, Public Health Wales, and Public 
Health Agency Northern Ireland, 2016). For the first time since the mid 1980s, the number of new 
annual HIV diagnoses among PWID was higher than in other high-risk groups including men who 
have sex with men (MSM). Outbreak investigation has established that this increase is due to active 
transmission among PWID. Those affected are typically injecting heroin with or without cocaine in a 
city centre environment where equipment sharing has been identified, and many are homeless. The 
outbreak response is multi-agency and includes awareness raising and HIV education among PWID 
and service staff, increasing availability of Injecting Equipment Provision (IEP) services, increasing 
HIV testing, and promoting early treatment to reduce the risk of onward transmission. One 
additional component of the response relevant to the work of Kesten and colleagues is the 
introduction of detachable LDSS to PWID accessing IEP services in Glasgow. The supply of LDSS to 
PWID to reduce BBV transmission risk is recommended by both the World Health Organization 





Outbreak investigation identified that, whilst fixed 1ml LDSS were available, the majority of cases 
had recently accessed 2ml syringes from IEP services. The standard design of the 2ml syringes 
available to PWID in Glasgow at that time was high risk for blood-borne viruses by nature, as they 
trap blood and fluid in the hub as well as holding enough drug solution to be shared when preparing 
a batch. The incident management team sought to address this urgently. Available low dead space 
needles were found to be incompatible with the standard 2ml syringes in the one-hit-kits® (1HK®). 
We therefore worked with our supplier1 to design a new LDSS to fit all separate needles, regardless 
of manufacturer. A LDSS which incorporated an extended plunger was developed, lab tested and 
shown to reduce ‘post injection’ blood and fluid content by 70%. This is equivalent to separate low 
dead space needles. (Figure 1) 
Eight samples of the new LDSS were reviewed by frontline professionals at the Scottish Needle 
Exchange Workers Forum for testing and feedback to inform implementation in Glasgow with no 
problems identified. In addition, the proposed switch to LDSS in Glasgow was presented to the 
National Blood-Borne Virus Prevention Leads meeting where it was also endorsed. 
In the past, when new equipment has become available for PWID (e.g. 1HK®, filter syringes, water, 
foil) we have designed and implemented these changes with initial pilots, peer involvement and 
supported the introduction with information materials for clients and training for staff.  
 However, within an outbreak situation, we proceeded to introduce the LDSS into our 1HK® without 
promotion to, or training with, PWID for the following reasons: 
1. The outbreak was ongoing with considerable risk of further transmission. 
2. For PWID, there is no difference to the mechanics of injection or presentation of the new 
low dead space product. The only change has been the introduction of an improved plunger; 
the needle and the syringe were unchanged, it remains detachable and they were in the 
standard 1HK® packaging. 
3. There were concerns that promoting low dead space products as a means of reducing the 
likelihood of BBV transmission may infer to PWID that they are ‘safe to share’. Similarly, 
promoting low dead space products as ‘full-dose’ syringes may also encourage people to 
share when dividing a supply of drugs for use among a network of peers. 
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4. The safest needle for PWID to use remains the 1ml fixed syringe and continues to be 
promoted as such within IEP services. All needles, syringes and related paraphernalia remain 
single use, packaged and promoted as such i.e. 1HK®. 
Staff were briefed to enable them to respond appropriately to any issues or questions that arose. 
The initial experience of implementing low-dead space syringes into the available 1HK® in Glasgow 
has been overwhelmingly positive. Almost 300,000 LDSS have been supplied as part of the IEP 
programme within the city in the first 6-months since they were introduced in April 2016. To date, 
there have been no issues identified by clients or staff in relation to their distribution or use.  
Moreover, by virtue of a national procurement contract in Scotland for IEP equipment, the 2ml LDSS 
pioneered in Glasgow are currently being rolled out across Scotland.  
We accept the conclusions of Kesten et al (2017) regarding the difficulties in changing injecting 
equipment and the need for information to empower PWID to enhance their acceptability. However, 
faced with a rapidly transmitting outbreak of HIV among a large at-risk population, we adopted an 
alternative approach to implementation which effectively replaced existing stock with a new low 
dead space product quickly, with minimal disruption and without promotion. Our next steps involve 
formally evaluating the impact of LDSS circulation on BBV incidence and prevalence pre and post 
introduction in Scotland.  
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Figure 1: comparison of old 2ml syringe (bottom) and new 2ml low dead space syringe (top) 
incorporating extended plunger 
 
 
 
 
